Uniphar | Development

Uniphar is pleased to announce the appointment of Dedra Ward as Vice President of Human Resources, Uniphar U.S. Dedra is a seasoned HR executive with more than 20 years of experience leading organizational transformation across Fortune 500 companies. She has extensive expertise in mergers, system implementations, restructuring, and aligning business and people strategies to build high-performing cultures. Having begun her career in IT, Dedra brings a unique blend of technical insight and human-centered leadership. She holds an MBA and is a member of the Forbes HR Council, where she contributes thought leadership on transformation, leadership, and talent development. Dedra’s leadership will help strengthen the people and capabilities behind a business that spans Development, Clinical, Access, Medical, Commercial, Distribution, and Global Sourcing—supporting customers across the full product lifecycle, from molecule to market and beyond. Please join us in welcoming Dedra to Uniphar—we are delighted to have her on board.

Every FDA meeting is a high-stakes interaction. The agency's agenda will always evolve — yours must be ready no matter what. The sponsors who get the most out of their FDA interactions, tend to do the same things well: ✅ Well-structured briefing document that provides FDA with the information needed to answer the question before it's asked ✅ Short, prioritized list of questions — not a wish list ✅ Clear internal alignment on what "success" looks like before the meeting starts ✅ Preparation that includes the uncomfortable scenarios We captured the full framework in our FDA Meeting Mastery Guide. If your team has a meeting on the calendar this year, we'd love to get it in your hands. Comment "GUIDE" below or send us a message. #FDA #RegulatoryStrategy #Pharma #DrugDevelopment #RegulatoryAffairs

From the floor of ISCT, International Society for Cell & Gene Therapy in Dublin, Ireland (hometown of Uniphar), hear from Maurice Leonard on our unique ability to evolve cell and gene therapies. #isct2026 #CGT #cellandgene #Uniphar #drugdevelopment 

Our own Mark Leney is in Dublin ready for the excitement, exploration, and education of ISCT, International Society for Cell & Gene Therapy. Are you there too? Stop by booth 2213 and say "hi" to Mark and the Uniphar team. #ISCT2026 #CellandGeneTherapy #CGT #DrugDevelopment #Biotech #LifeScience #Uniphar

ISCT has landed in Dublin—home town of Uniphar. As you step into the lobby, you’re welcomed to ISCT, International Society for Cell & Gene Therapy by Uniphar and the start of our discussions on how development lays the groundwork for successful cell and gene therapy commercialization. This is where the week begins. More to come on the conversations shaping cell & gene therapy. 📍 Visit us at Booth 2213 #ISCT2026 #CellAndGeneTherapy #CGT #DrugDevelopment #Biotech #LifeSciences #Uniphar

Looking to navigate the complexities of advanced therapy development? Uniphar will be at the ISCT, International Society for Cell & Gene Therapy Annual Meeting to support execution of your cell and gene therapy development program. We support partners to connect the dots from concept to commercial including: -Early CMC, science, technical development, and outsourcing strategy -IND‑enabling and first‑in‑human program support -Integration with global clinical, regulatory, and commercialization expertise -End‑to‑end advanced therapy development and delivery pathways If you’re heading to ISCT, we’d love to connect. Reach out directly or stop by Booth 2213 to discuss your program. #ISCT2026 #CellAndGeneTherapy #AdvancedTherapies

Challenges arise in drug development when disciplines such as CMC, clinical pharmacology, regulatory strategy, and clinical execution aren’t fully aligned. Uniphar Development brings these capabilities together within an integrated development team, helping Sponsors navigate complex decisions across NMEs and 505(b)(2) programs with greater confidence. Connect with our experts to learn how integrated drug development expertise can simplify complex decisions and support program success.

Many drug development delays can be traced back to strategic gaps discovered too late. When key clinical pharmacology questions remain unanswered, teams may find themselves redesigning studies or defending assumptions during regulatory reviews. Uniphar Development’s seasoned experts approach clinical pharmacology with a “right-the-first-time” mindset—prioritizing work that adds value to the asset at each step and results in better interactions with regulators. Reach out to learn more.

Phase 1 studies do more than establish initial safety. Study design, characterization of the PK, exposure-response (PK/PD), informed dose selection, and dosing interval strategy all influence how regulators view an asset’s potential. Uniphar Development partners with Sponsors to design Phase 1 programs to characterize PK and develop the exposure-response relationships across dose levels that are needed to guide later development. Reach out to connect with our Clinical Pharmacology & Pharmacometrics experts to explore strategic study design. 

Today is World Health Day – a time to recognize the importance of science in improving and protecting global health. Meaningful progress depends on strong collaboration across the healthcare ecosystem, turning scientific discovery into real-world impact. We’re proud to support the pharma industry in driving innovation, accelerating development, and helping to deliver better health outcomes worldwide.